Dihexa
Also known as: PNB-0408, PNB0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
3 notable studies · 4 references
TLDR
Dihexa is an experimental blood-brain-barrier-penetrant angiotensin-IV-derived small molecule that enhances HGF/c-Met signaling and promotes synapse formation and cognitive improvement in preclinical models, but controlled human efficacy and safety evidence is essentially absent.
Research Supports
- Studied for synaptogenesis and dendritic-spine formation in neuronal preparations
- Investigated for HGF/c-Met signaling as a mechanism of neural plasticity
- Studied for effects on learning and memory in rodent models
- Investigated as an experimental strategy for Alzheimer's, Parkinson's, and Huntington's disease models
- Raises theoretical safety questions given HGF/c-Met's broader role in cell growth and cancer biology
Observations Reported in Research
- Bound HGF with high affinity and enhanced HGF-dependent c-Met activation, increasing hippocampal spinogenesis and synaptogenesis (McCoy et al., 2014)
- Blocking HGF/c-Met signaling prevented the procognitive effects in a rodent spatial-learning task (McCoy et al., 2014)
- Review described improved memory and motor function across preclinical AngIV-analogue models (Wright & Harding, 2015)
- Reported neuroprotective/procognitive signals in a rat Huntington's-like neurodegeneration model (2024)
- No robust human trials have demonstrated cognitive, Alzheimer's, Parkinson's, or Huntington's benefits
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic angiotensin IV-derived peptidomimetic; HGF/c-Met modulator; experimental neurotrophic small molecule
Dihexa is an experimental small molecule derived from angiotensin IV research and developed to penetrate the blood-brain barrier. It is not a conventional peptide. It is better described as a peptidomimetic / small-molecule AngIV analogue. Researchers have studied Dihexa for: • Synaptogenesis • Learning and memory • Alzheimer's disease • Parkinson's disease • Neurodegeneration • Huntington's disease • HGF/c-Met signaling Its most interesting proposed mechanism involves: HGF — hepatocyte growth factor and its receptor: c-Met. Experiments indicate that Dihexa binds HGF and enhances HGF-dependent c-Met activation, promoting formation of dendritic spines and functional synapses. This produced striking procognitive effects in animal models. But the critical reality check is: Dihexa does not have established human clinical efficacy for Alzheimer's disease, cognitive enhancement, Parkinson's disease, or other neurological disorders. Its reputation is dramatically ahead of its human evidence.
What Is Dihexa?
Dihexa emerged from research on angiotensin IV (AngIV). AngIV and related compounds had demonstrated intriguing effects on: • Learning • Memory • Cerebral blood flow • Neural plasticity Researchers therefore developed modified molecules with improved: • Metabolic stability • Oral activity • Blood-brain-barrier penetration One result was: Dihexa / PNB-0408. Its chemical name is: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Research subsequently suggested that the cognitive biology of Dihexa and related AngIV analogues involves the HGF/c-Met system.
What Are Researchers Studying?
Synaptogenesis
This is probably Dihexa's most distinctive research area. Synaptogenesis means formation of new functional connections between neurons. In hippocampal neuronal preparations, Dihexa increased dendritic-spine formation. Importantly, the new structures were associated with presynaptic markers and increased excitatory synaptic currents, supporting the interpretation that functional synapses were being formed. This is much more specific than simply saying Dihexa is “neurotrophic.” But it remains preclinical.
HGF/c-Met signaling
HGF is a growth factor that binds the receptor tyrosine kinase c-Met. This system participates in: • Cell survival • Migration • Tissue repair • Development • Neurogenesis • Neuronal growth • Synaptic plasticity Researchers found that Dihexa binds HGF with high affinity and enhances HGF-dependent activation of c-Met. Dihexa alone did not simply behave as a conventional direct c-Met agonist under every experimental condition. Instead, it appeared to potentiate HGF signaling. That's an important mechanistic nuance.
Learning and memory
Dihexa improved performance in experimental learning and memory paradigms in rodents. Most importantly, blocking HGF/c-Met signaling also blocked Dihexa's procognitive effects in a Morris water-maze experiment. That strengthens the argument that the HGF/c-Met pathway actually participates in the observed cognitive phenotype rather than merely changing alongside it. Still: Improved rodent maze performance ≠ proven human cognitive enhancement.
Alzheimer's disease
Dihexa was developed partly as a potential therapeutic strategy for Alzheimer's disease. The rationale is different from current anti-amyloid therapies. Instead of primarily trying to remove a pathological protein, Dihexa research asks whether enhancing synaptic connectivity and neurotrophic signaling could improve cognition despite underlying pathology. Reviews describe Dihexa as an orally active, blood-brain-barrier-permeable AngIV analogue with procognitive activity in animal models. However, this remains an experimental strategy. There is no established evidence that Dihexa slows or reverses Alzheimer's disease in humans.
Parkinson's disease
The HGF/c-Met system also has neuroprotective properties relevant to dopaminergic neurons. AngIV-derived molecules including Dihexa have therefore been investigated in experimental Parkinson's disease models. Reviews report improvements in memory and motor systems in preclinical neurodegenerative models. Human Parkinson's efficacy remains unestablished.
Huntington's disease
More recent research expanded Dihexa into a rat model of Huntington's-like neurodegeneration. In a 2024 study using 3-nitropropionic acid, Dihexa/PNB-0408 was evaluated for effects on: • Spatial learning • Memory • Motor function • Neuropathology. The experimental findings supported further investigation of Dihexa in neurodegenerative disease models. This remains animal research and should not be described as evidence for Huntington's treatment in humans.
How Does It Work?
The leading proposed pathway is: Dihexa ↓ binds/modulates HGF ↓ enhances HGF-dependent activation of c-Met ↓ intracellular growth/plasticity signaling ↓ spinogenesis + synaptogenesis ↓ improved neural connectivity ↓ procognitive effects in experimental animals. HGF/c-Met signaling affects numerous downstream pathways, including those involved in: • AKT • ERK/MAPK • cell survival • cytoskeletal remodeling • neuronal growth. This mechanism also raises a major safety question. The c-Met issue c-Met isn't merely a “brain-growth receptor.” HGF/c-Met signaling also participates in: • Cell proliferation • Migration • Angiogenesis • Tissue regeneration And dysregulated c-Met signaling is implicated in multiple cancers. That does not mean: “Dihexa causes cancer.” There is no adequate human evidence to make that claim. But a compound designed to potentiate HGF/c-Met signaling raises a legitimate theoretical safety question that would require careful investigation before chronic human use. That's exactly the kind of nuance Aminodex should preserve.
What Does the Research Show?
Human research
Direct therapeutic human evidence for Dihexa is essentially absent from the established peer-reviewed clinical literature. There are no robust human trials demonstrating that Dihexa: • Improves cognition • Treats Alzheimer's disease • Treats Parkinson's disease • Treats Huntington's disease • Reverses dementia • Enhances memory in healthy adults This means almost all efficacy claims currently trace back to: cellular experiments + animal models + mechanistic inference.
Animal research
Animal research is the strongest evidence base. Dihexa and related AngIV analogues have been studied in models involving: • Cognitive impairment • Alzheimer's-like dysfunction • Parkinsonian dysfunction • Huntington's-like neurodegeneration • Learning and memory. The results provide an interesting proof of concept for HGF/c-Met manipulation in neural plasticity.
In-vitro research
This is particularly strong mechanistically. Researchers demonstrated: • High-affinity Dihexa-HGF binding • Enhancement of HGF-dependent c-Met phosphorylation • Increased dendritic-spine formation • Increased functional synaptic connectivity • Dependence of several effects on HGF/c-Met signaling. That makes the mechanism much better developed than the clinical evidence, which remains minimal.
Notable Studies
The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System
animalResearchers investigated how Dihexa and related AngIV analogues produce procognitive effects. Dihexa bound HGF with high affinity, enhanced HGF-dependent c-Met activation, and increased hippocampal spinogenesis and synaptogenesis. Blocking HGF/c-Met signaling prevented both synaptic effects and Dihexa's procognitive activity in a rodent spatial-learning task.
Limitations: Preclinical research using cells, brain preparations and rodents. It establishes a plausible mechanism but not human efficacy or safety.
View publication →The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's Diseases
animalResearchers summarized development of metabolically stable AngIV analogues capable of entering the brain, including Dihexa. The review describes preclinical evidence for improved memory and motor function and discusses HGF/c-Met-mediated synaptic connectivity as a potential therapeutic strategy.
Limitations: Review of preclinical research rather than human clinical evidence.
View publication →Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats
animalForty male Wistar rats were used to examine whether PNB-0408/Dihexa could modify cognitive, motor and pathological changes caused by chronic 3-nitropropionic-acid exposure. The study reported neuroprotective/procognitive signals supporting further investigation of the compound in neurodegeneration.
Limitations: Chemically induced rat disease models do not reproduce the full genetic and progressive biology of human Huntington's disease. No human therapeutic inference can be made directly.
View publication →What We Still Don't Know
A lot: • Human safety • Human pharmacokinetics • Human oral bioavailability • Effective human exposure • Long-term neurological effects • Whether synaptogenesis occurs in the human brain • Whether increased synaptic density would actually improve human cognition • Effects in healthy people • Effects in Alzheimer's disease • Effects in Parkinson's disease • Effects in Huntington's disease • Long-term HGF/c-Met consequences • Cancer-related risk • Cardiovascular safety • Liver effects • Reproductive safety • Drug interactions • Whether chronic c-Met potentiation produces receptor adaptation • Whether research-market Dihexa matches experimentally characterized material
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Dihexa research with you.
Get the Aminodex Dihexa Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- McCoy AT, Benoist CC, Wright JW, et al. The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. 2014.
- Wright JW, Harding JW. The Development of Small Molecule Angiotensin IV Analogs to Treat Alzheimer's and Parkinson's Diseases. 2015.
- The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. 2015.
- Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. 2024.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.